Alkermes plc (NASDAQ:ALKS) SVP Sells $151,813.20 in Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 5,208 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. The trade was a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alkermes Stock Performance

ALKS opened at $29.02 on Friday. The stock’s 50 day simple moving average is $28.01 and its 200 day simple moving average is $26.52. The stock has a market cap of $4.70 billion, a P/E ratio of 14.88, a P/E/G ratio of 0.97 and a beta of 0.47. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $32.88. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03.

Institutional Trading of Alkermes

Several large investors have recently bought and sold shares of ALKS. O Shaughnessy Asset Management LLC boosted its position in shares of Alkermes by 21.2% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 11,976 shares of the company’s stock worth $324,000 after buying an additional 2,097 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of Alkermes by 19.6% in the first quarter. Advisors Asset Management Inc. now owns 29,886 shares of the company’s stock valued at $809,000 after purchasing an additional 4,891 shares in the last quarter. Lazard Asset Management LLC grew its position in shares of Alkermes by 655.0% in the first quarter. Lazard Asset Management LLC now owns 77,102 shares of the company’s stock valued at $2,087,000 after purchasing an additional 66,890 shares during the last quarter. Bayesian Capital Management LP purchased a new position in shares of Alkermes during the 1st quarter worth approximately $333,000. Finally, Tidal Investments LLC acquired a new position in shares of Alkermes during the 1st quarter worth approximately $441,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ALKS. Mizuho increased their price target on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and issued a $37.00 target price (down previously from $38.00) on shares of Alkermes in a research note on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. JPMorgan Chase & Co. reduced their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Cantor Fitzgerald dropped their target price on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.